NEW YORK (GenomeWeb News) – Quantum Materials and NanoAxis have forged a deal combining their technologies for diagnostic and pharmaceutical applications.
As part of a deal announced on Wednesday, the two companies will develop quantum dot-based microarray assays for the real-time measurement of cancer biomarkers for research, clinical applications, and product development.
Quantum dots are some of the smallest man-made molecules, the companies said, and their high surface-to-volume ratio provides "excellent" binding affinity for antibodies, peptides, nucleic acids, and other ligands.
Quantum Materials, based in Tempe, Ariz., and NanoAxis, headquartered in Buffalo, NY., will develop new nanomedicine products using Quantum's tetrapod quantum dots and other quantum dot semiconductor nanocrystals to serve as multiplexing platforms for NanoAxis' theranostic therapies in targeting receptors, imaging cells and tissues, and drug delivery of pharmaceutical compounds.
Financial and other terms of the deal were not disclosed.